Refine by
Clinical Toxicology Equipment & Supplies
6 equipment items found
Manufactured by:AZER Scientific based inMorgantown, PENNSYLVANIA (USA)
Azer Scientific's re-closable zipper top biohazard specimen transport bags provide an excellent solution for securely transporting various specimens to and from the laboratory. Ideal for hospital, doctor's office and reference lab use, our biohazard specimen bags are manufactured from the highest quality LDPE material, 2 mil thickness with a three wall design. A separate pouch with flap allows ...
Manufactured by:Randox Toxicology based inCrumlin, UNITED KINGDOM
Biochip Array Technology is a immunoassay testing platform allowing for the simultaneous multi-analyte testing of a panel of related tests. The technology works by combining a panel of up to 44 related tests on a single Biochip with a single set of reagents, controls and calibrators. Competitive chemiluminescent immunoassays are employed for the Biochip Arrays. A light signal generated from each ...
Manufactured by:CML Biotech (P) Ltd. based inErnakulam Dist., INDIA
Centrifuge at 2000-3000 rpm for 10 min. at room temperature. Used for emergency Biochemistry test, Endocrine and metabolic disorders, Therapeutic Drug monitoring and Toxicology, Electrolytes, Clinical chemistry, Serology and immunology etc. Lithium test should not be performed using Lithium Heparin tubes. ...
Manufactured by:CML Biotech (P) Ltd. based inErnakulam Dist., INDIA
Used for emergency Biochemistry test, but also for Endocrine and metabolic disorders, Therapeutic Drug monitoring and Toxicology, Electrolytes, Clinical chemistry, Serology and immunology etc. Centrifuge at 2000-3000 rpm for 10 min. at room temperature. ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Many intravenously delivered Active Pharmaceutical Ingredients (APIs) are insoluble or poorly soluble in water. This can be a major hurdle in pharmaceutical development and may cause promising drugs to fail during the development process and may limit the application of approved drugs because of poor solubility. According to some estimates, between 70 and 90% of drugs in the development pipeline ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...